
Amendment to the Claims:

 (Original) A polyethylenimine polymer according to the following formula:



wherein α is between 0 to 90%; β is between 0 to 100%; γ is between 0 to 50%;

wherein $\alpha + \beta + \gamma = 100\%$; and

the Z groups are hydrophobic and are independently hydrogen or any linear or branched, substituted or unsubstituted, or cyclo form of any hydrophobic substituent; and

Y may represent a hydrophilic substituent.

- 2. (Original) A polyethylenimine polymer according to claim 1 wherein the monomer units identified with α , β and γ form any arrangement in the polyethylenimine polymer.
- 3. (Original) A polyethylenimine polymer according to claim 1 wherein the arrangement of the α , β and γ units are random or in a block copolymer form such as $\alpha\beta\gamma\alpha\beta\gamma\alpha\beta\gamma$.

4.-31. (Canceled)

32. (Currently amended) A method of forming a polyethylenimine polymer according to <u>claim lany of claims 1 to 31</u> by

reacting a polyethylenimine compound formed from the polymerisation of ethylenimine with a first organo halide to form an organo side chain on the polyethylenimine compound, and then a second organo halide to react with an amino group on the polyethylenimine compound.

33. (Original) A method according to claim 32 wherein the ethylenimine is branched or linear.

34.-43. (Canceled)

- 44. (Currently amended) A composition comprising a polyethylenimine polymer according to <u>claim 1</u> any of claims 1 to 31 and a pharmaceutically acceptable carrier.
- 45. (Canceled)
- 46. (Currently amended) A pharmaceutical composition comprising a polyethylenimine polymer according to claims 1 to 31 and a drug.
- 47. (Original) A pharmaceutical composition according to claim
 46 wherein the drug is poorly soluble in aqueous solvents
 such as water.
- 48. (Currently amended) A pharmaceutical composition according to <u>claim 46</u> any of claims 46 and 47 wherein the drug is selected from any of the following: cyclosporin; steroids such as prednisolone, oestradiol, testosterone; drugs with multicyclic ring structures which lack polar groups such as paclitaxel; and drugs such as etoposide.

49.-57. (Canceled)